首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer
【24h】

Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer

机译:Clostridium perfringens肠毒素C-末端结构域标记为荧光染料,用于体内可视化微转移化疗抗性卵巢癌

获取原文
获取原文并翻译 | 示例
           

摘要

Identification of micrometastatic disease at the time of surgery remains extremely challenging in ovarian cancer patients. We used fluorescence microscopy, an in vivo imaging system and a fluorescence stereo microscope to evaluate fluorescence distribution in Claudin-3- and -4-overexpressing ovarian tumors, floating tumor clumps isolated from ascites and healthy organs. To do so, mice harboring chemotherapy-naive and chemotherapy-resistant human ovarian cancer xenografts or patient-derived xenografts (PDXs) were treated with the carboxyl-terminal binding domain of the Clostridium perfringens enterotoxin (c-CPE) conjugated to FITC (FITC-c-CPE) or the near-infrared (NIR) fluorescent tag IRDye CW800 (CW800-c-CPE) either intraperitoneally (IP) or intravenously (IV). We found tumor fluorescence to plateau at 30 min after IP injection of both the FITC-c-CPE and the CW800-c-CPE peptides and to be significantly higher than in healthy organs (p < 0.01). After IV injection of CW800-c-CPE, tumor fluorescence plateaued at 6 hr while the most favorable tumor-to-background fluorescence ratio (TBR) was found at 48 hr in both mouse models. Importantly, fluorescent c-CPE was highly sensitive for the in vivo visualization of peritoneal micrometastatic tumor implants and the identification of ovarian tumor spheroids floating in malignant ascites that were otherwise not detectable by conventional visual observation. The use of the fluorescent c-CPE peptide may represent a novel and effective optical approach at the time of primary debulking surgery for the real-time detection of micrometastatic ovarian disease overexpressing the Claudin-3 and -4 receptors or the identification of residual disease at the time of interval debulking surgery after neoadjuvant chemotherapy treatment.
机译:在手术时鉴定微转移疾病在卵巢癌患者中仍然极其挑战。我们使用荧光显微镜,体内成像系统和荧光立体显微镜,以评估Claudin-3-and -4-过度抑制卵巢肿瘤中的荧光分布,从腹水和健康器官中分离出浮动肿瘤丛。为此,用蛋白纤维素肠毒素(C-CPE)与FITC(FITC-)的羧基 - 末端结合结构域处理含有化疗 - 幼稚和化疗抗性的人卵巢癌异种移植物或患者衍生的异种移植物(PDXS)的小鼠。 C-CPE)或近红外(NIR)荧光标签IRDYE CW800(CW800-C-CPE)腹膜内(IP)或静脉内(IV)。在IP注射FITC-C-CPE和CW800-C-CPE肽的IP注射后30分钟发现肿瘤荧光至高原,并明显高于健康器官(P <0.01)。在IV注射CW800-C-CPE后,在6小时的肿瘤荧光下柔韧,而在两种小鼠模型中以48小时发现最有利的肿瘤到背景荧光比(TBR)。重要的是,荧光C-CPE对腹膜微转移肿瘤植入物的体内可视化对漂浮在恶性腹水中的卵巢肿瘤球状体的鉴定,其常规视觉观察不可检测。荧光C-CPE肽的使用可以在初级消除手术时代表一种新颖且有效的光学方法,用于实时检测克劳蛋白-3和-4受体的微转移卵巢疾病或鉴定残留疾病新辅助化疗治疗后间隔渗透手术的时间。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号